Global Non-Small Cell Lung cancer Market Research and Forecast 2018-2023

  • ID: 4471511
  • Report
  • Region: Global
  • Orion Market Research Private Limited
15 % OFF
until Jul 31st 2018
1 of 4

FEATURED COMPANIES

  • Abbvie
  • Bayer
  • Celgene
  • Eli Lilly And CoMPany
  • Merck & Co. Inc.
  • Pharmacyclics
  • MORE
Non-small cell lung cancer market is anticipated to grow at a CAGR of 8.6% by 2023. Lung cancer starts when cells of the lung become abnormal and begin to grow out of control. As more cancer cells develop, they form into a tumor and spread to other areas of the body. The non-small cell lung cancer is a type of lung cancer. Several factors that cause lung cancer include pollution, smoking, passive smoking and other factors. Hereditary causes of cancer is another factor that drives the global non-small cell lung cancer diagnostics and therapeutics market.

Rising pollution due to the amount of carbon particles inhaled by humans cause several problems including lung cancer. Several factors that drive the market include robust healthcare expenditure within developed countries, increasing pollution, government initiatives for lung cancer, and rising cases of smoking. There are several signs and symptoms of lung cancer such as coughing up blood, weight loss, chest pain, shortness of breath and others. According to the National Cancer Institute, an estimated number of deaths due to lung cancer was around 155,000 in 2017.

The non-small cell lung cancer diagnosis and therapeutics market has been segmented based on by type, by treatment, by diagnosis, by stages and by end user. On the basis of type, the market has been bifurcated into squamous cell carcinoma, large cell carcinoma, adenocarcinoma and others. According to therapy, the market is segmented into chemotherapy, targeted therapy, radiation therapy, surgery, cryosurgery and others. Based on diagnosis, the market has been bifurcated into CT-scan, X-rays, laboratory test, bronchoscopy, sputum cytology, thoracoscopy and others. On the basis of end user, the market has been bifurcated into multispecialty hospitals and cancer research centers.

Geographically, the worldwide non-small cell lung cancer diagnosis and therapeutics market is divided into North America, Europe, Asia-Pacific, and Rest of the World. Asia Pacific market is considered to be the fastest growing market globally. The rise in the number of cancer patients in the APAC region is considered to rise eventually enabling the lung cancer diagnosis and therapeutics market to grow. North America and Europe are considered to be the dominating markets due to various factors such as high healthcare expenditure, development in technology, support from government, rise in key players and various other factors.

The key players in the non-small cell lung cancer diagnosis and therapeutics market include Astrazeneca PLC, Eli lilly and company Sanofi-Aventis, Arqule Inc, Daiichi Sankyo co. Ltd, Celgene, Merck, Pfizer, Ventana, Roche, Genentech, Glaxosmith, Boehringer, Novartis, Bayer, Bristol-Myers Squibb, Eisai, AbbVie, Pharmacyclics.

Market Segmentation:

Global non-small cell lung cancer diagnosis and therapeutics market is segmented on the basis of, type, by therapies, by, diagnosis, by end user and regional outlook.
  • Global Non-Small Cell Lung cancer diagnosis and therapeutics Market Research and Analysis, By Type
  • Global Non-Small Cell Lung cancer diagnosis and therapeutics Market Research and Analysis, By Therapies
  • Global Non-Small Cell Lung cancer diagnosis and therapeutics Market Research and Analysis, By Diagnosis
  • Global Non-Small Cell Lung cancer diagnosis and therapeutics Market Research and Analysis, By End User
  • Global Non-Small Cell Lung cancer diagnosis and therapeutics Market Research and Analysis, By Region
The Reports Covers:
  • Comprehensive research methodology of Global Non-Small Cell Lung cancer diagnosis and therapeutics
  • This report also includes detailed and extensive market overview with key analyst insights.
  • Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the Global Non-Small Cell Lung cancer diagnosis and therapeutics
  • Insights about market determinants which are stimulating the Global Non-Small Cell Lung cancer diagnosis and therapeutics
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abbvie
  • Bayer
  • Celgene
  • Eli Lilly And CoMPany
  • Merck & Co. Inc.
  • Pharmacyclics
  • MORE
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. by Segments
1.2.2. by Geography
1.2.3. by Stakeholders

2. Market Overview and Insights
2.1. Definition
2.2. Analyst Insights & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendation
2.2.3. Conclusion
2.3. Regulations
2.3.1. United States
2.3.2. European Union
2.3.3. China
2.3.4. India
2.3.5. Rest of the World
2.4. Patent Analysis

3. Market Determinant
3.1. Motivators
3.1.1. Rising Utilization of Combine Therapies
3.1.2. Government Initiatives for Improving the Awareness Among Individuals
3.1.3. Rising Levels Pollution Due to Urbanization Increases Cases of Lung Cancer
3.1.4. High Prevalance of Lung Cancer and Lung Related Issues Due Smoking
3.1.5. Investments in Cancer Drug Discovery and Biomarker Identification
3.2. Restraints
3.2.1. High Cost Associated With Lung Cancer Therapies
3.2.2. Unmet Need & Diagnosis in Under Developed Nation
3.2.3. Adverse Effects of Drugs During Treatment
3.3. Opportunities
3.3.1. R&D in the Therapies and Drugs
3.3.2. Strategic Alliance for Late-Stage Pipeline

4. Market Segmentation
4.1. Global Non-Small Cell Lung Cancer Diagnosis and Therapeutics Market, by Type
4.1.1. Adenocarcinomas
4.1.2. Squamous Cell Carcinoma
4.1.3. Large Cell Carcinomas
4.1.4. Others
4.2. Global Non-Small Cell Lung Cancer Diagnosis and Therapeutics Market, by Therapy
4.2.1. Chemotherapy
4.2.2. Targeted Therapy
4.2.3. Radiation Therapy
4.2.4. Surgery
4.2.5. Cryosurgery
4.2.6. Others
4.3. Global Non-Small Cell Lung Cancer Diagnosis and Therapeutics Market, by Diagnosis
4.3.1. CT Scan
4.3.2. X-Rays
4.3.3. Sputum Cytology
4.3.4. Bronchoscopy
4.3.5. Laboratory Tests
4.3.6. Thoracoscopy
4.3.7. Others
4.4. Global Non-Small Cell Lung Cancer Diagnosis and Therapeutics Market, by End User
4.4.1. Multispeciality Hospitals
4.4.2. Cancer Research Centers

5. Competitive Landscape
5.1. Strategy Analysis
5.2. Key Company Analysis

6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. United Kingdom
6.2.2. France
6.2.3. Germany
6.2.4. Italy
6.2.5. Spain
6.2.6. Rest of Europe
6.3. Asia Pacific
6.3.1. India
6.3.2. China
6.3.3. Japan
6.4. Rest of the World

7. Company Profiles
7.1. Abbvie
7.2. Arqule Inc.
7.3. Astrazeneca PLC
7.4. Bayer
7.5. Boehringer
7.6. Bristol-Myers Squibb
7.7. Celgene
7.8. Daiichi Sankyo Co. Ltd.
7.9. Eisai
7.10. Eli Lilly and Company
7.11. Genentech
7.12. Glaxosmith
7.13. Merck & Co. Inc.
7.14. Novartis International Ag
7.15. Pfizer
7.16. Qiagen N.V. Company
7.17. Pharmacyclics
7.18. Roche
7.19. Sanofi
7.20. Teva Pharmaceuticals
7.21. Ventana
7.22. Valeant Pharmaceuticals Inc.
7.23. Varian Medical Systems Inc.

List of Tables:
Table 1 Global Non-Small Cell Lung Cancer Diagnosis and Therapeutics Market Research and Analysis, by Geography, 2017-2023($Million)
Table 2 Global Non-Small Cell Lung Cancer Diagnosis and Therapeutics Market Research and Analysis, by Type 2017-2023($ Million)
Table 3 Global Adenocarcinomas Market Research and Analysis, 2017-2023, ($ Million) 2022, ($ Million)
Table 4 Global Sarcomas Cell Carcinoma Market Research and Analysis, 2017-2023, ($ Million)
Table 5 Global Large Cell Carcinoma Market Research and Analysis, 2017-2023, ($ Million)
Table 6 Global Others Market Research and Analysis, 2017-2023, ($ Million)
Table 7 Global Non-Small Cell Lung Cancer Diagnosis and Therapeutics Market Research and Analysis, by Therapy 2017-2023($ Million)
Table 8 Global Chemotherapy Market Research and Analysis, 2017-2023, ($ Million)
Table 9 Global Targeted Therapy Market Research and Analysis, 2017-2023, ($ Million)
Table 10 Global Radiotherapy Market Research and Analysis, 2017-2023, ($ Million)
Table 11 Global Surgery Market Research and Analysis, 2017-2023, ($ Million)
Table 12 Global Cryosurgery Market Research and Analysis, 2017-2023, ($ Million)
Table 13 Global Others Market Research and Analysis, 2017-2023, ($ Million)
Table 14 Global Non-Small Cell Lung Cancer Diagnosis and Therapeutics Market Research and Analysis, by Diagnosis, 2017-2023, ($ Million)
Table 15 Global Ct-Scan Market Research and Analysis, 2017-2023, ($ Million)
Table 16 Global X-Rays Market Research and Analysis, 2017-2023, ($ Million)
Table 17 Global Sputum Cytology Screening Market Research and Analysis, 2017-2023, ($ Million)
Table 18 Global Bronchoscopy Market Research and Analysis, 2017-2023, ($ Million)
Table 19 Global Laboratory Test Market Research and Analysis, 2017-2023, ($ Million)
Table 20 Global Thoracoscopy Market Research and Analysis, 2017-2023, ($ Million)
Table 21 Global Others Market Research and Analysis, 2017-2023, ($ Million)
Table 22 Global Non-Small Cell Lung Cancer Diagnosis and Therapeutics Market Research and Analysis, by End User 2017-2023, ($ Million)
Table 23 Global Multispecialty Hospitals Market Research and Analysis, 2017-2023, ($ Million)
Table 24 Global Cancer Research Institute Market Research and Analysis, 2017-2023, ($ Million)
Table 25 Merger and Acquisition
Table 26 Global Non-Small Cell Lung Cancer Diagnosis and Therapeutics Market, by Geography 2016-20122($ Million)
Table 27 North America Non-Small Cell Lung Cancer Diagnosis and Therapeutics Market Research and Analysis, by Type 2017-2023($Million)
Table 28 North America Non-Small Cell Lung Cancer Diagnosis and Therapeutics Market Research and Analysis, by Therapy 2017-2023($Million)
Table 29 North America Non-Small Cell Lung Cancer Diagnosis and Therapeutics Market Research and Analysis, by Diagnosis 2017-2023($Million)
Table 30 North America Non-Small Cell Lung Cancer Diagnosis and Therapeutics Market Research and Analysis, by End User 2017-2023($Million)
Table 31 North America Non-Small Cell Lung Cancer Diagnosis and Therapeutics Market Research and Analysis, by Countries 2017-2023($Million)
Table 32 Europe Non-Small Cell Lung Cancer Diagnosis and Therapeutics Market Research and Analysis, by Type 2017-2023($Million)
Table 33 Europe Non-Small Cell Lung Cancer Diagnosis and Therapeutics Market Research and Analysis, by Therapy 2017-2023($Million)
Table 34 Europe Non-Small Cell Lung Cancer Diagnosis and Therapeutics Market Research and Analysis, by Diagnosis 2017-2023($Million)
Table 35 Europe Non-Small Cell Lung Cancer Diagnosis and Therapeutics Market Research and Analysis, by End User 2017-2023($Million)
Table 36 Europe Non-Small Cell Lung Cancer Diagnosis and Therapeutics Market Research and Analysis, by Countries 2017-2023($Million)
Table 37 Asia Pacific Non-Small Cell Lung Cancer Diagnosis and Therapeutics Market Research and Analysis, by Type 2017-2023($Million)
Table 38 Asia Pacific Non-Small Cell Lung Cancer Diagnosis and Therapeutics Market Research and Analysis, by Therapy 2017-2023($Million)
Table 39 Asia Pacific Non-Small Cell Lung Cancer Diagnosis and Therapeutics Market Research and Analysis, by Diagnosis 2017-2023($Million)
Table 40 Asia Pacific Non-Small Cell Lung Cancer Diagnosis and Therapeutics Market Research and Analysis, by End User 2017-2023($Million)
Table 41 Asia Pacific Non-Small Cell Lung Cancer Diagnosis and Therapeutics Market Research and Analysis, by Countries 2017-2023($Million)
Table 42 Rest of the World Non-Small Cell Lung Cancer Diagnosis and Therapeutics Market Research and Analysis, by Type 2017-2023($Million)
Table 43 Rest of the Non-Small Cell Lung Cancer Diagnosis and Therapeutics Market Research and Analysis, by Therapy 2017-2023($Million)
Table 44 Rest of the World Non-Small Cell Lung Cancer Diagnosis and Therapeutics Market Research and Analysis, by Diagnosis 2017-2023($Million)
Table 45 Rest of the World Non-Small Cell Lung Cancer Diagnosis and Therapeutics Market Research and Analysis, by End User 2017-2023($Million)

List of Figures:
Figure 1 Global Non-Small Cell Lung Cancer Diagnosis and Therapeutics Market Share, by Type 2017 and 2023, (In %)
Figure 2 Global Non-Small Cell Lung Cancer Diagnosis and Therapeutics Market Share, by Therapy 2017 and 2023, (In %)
Figure 3 Global Non-Small Cell Lung Cancer Diagnosis and Therapeutics Market Share, by Diagnosis 2017 and 2023, (In %)
Figure 4 Global Non-Small Cell Lung Cancer Diagnosis and Therapeutics Market Share, by End User 2017 and 2023, (In %)
Figure 5 Global Non-Small Cell Lung Cancer Diagnosis and Therapeutics Market Share, by Geography 2017 and 2023, (In %)
Figure 6 North America Non-Small Cell Lung Cancer Diagnosis and Therapeutics Market Size, 2017-2023 ($Million)
Figure 7 US Non-Small Cell Lung Cancer Diagnosis and Therapeutics Market Size, 2017-2023 ($Million)
Figure 8 Canada Non-Small Cell Lung Cancer Diagnosis and Therapeutics Market Size, 2017-2023 ($Million)
Figure 9 European Non-Small Cell Lung Cancer Diagnosis and Therapeutics Market Size, 2017-2023 ($Million)
Figure 10 UK Non-Small Cell Lung Cancer Diagnosis and Therapeutics Market Size, 2017-2023 ($Million)
Figure 11 France Non-Small Cell Lung Cancer Diagnosis and Therapeutics Market Size, 2017-2023 ($Million)
Figure 12 Germany Non-Small Cell Lung Cancer Diagnosis and Therapeutics Market Size, 2017-2023 ($Million)
Figure 13 Italy Non-Small Cell Lung Cancer Diagnosis and Therapeutics Market Size, 2017-2023 ($Million)
Figure 14 Spain Non-Small Cell Lung Cancer Diagnosis and Therapeutics Market Size, 2017-2023 ($Million)
Figure 15 ROE Non-Small Cell Lung Cancer Diagnosis and Therapeutics Market Size, 2017-2023 ($Million)
Figure 16 Asia Pacific Non-Small Cell Lung Cancer Diagnosis and Therapeutics Market Size, 2017-2023 ($Million)
Figure 17 India Non-Small Cell Lung Cancer Diagnosis and Therapeutics Market Size, 2017-2023 ($Million)
Figure 18 China Non-Small Cell Lung Cancer Diagnosis and Therapeutics Market Size, 2017-2023 ($Million)
Figure 19 Japan Non-Small Cell Lung Cancer Diagnosis and Therapeutics Market Size, 2017-2023 ($Million)
Figure 20 RoAPAC Non-Small Cell Lung Cancer Diagnosis and Therapeutics Market Size, 2017-2023 ($Million)
Figure 21 Rest of the World Non-Small Cell Lung Cancer Diagnosis and Therapeutics Market Size, 2017-2023 ($
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Abbvie
  • Arqule Inc.
  • Astrazeneca Plc
  • Bayer
  • Boehringer
  • Bristol-Myers Squibb
  • Celgene
  • Daiichi Sankyo Co. Ltd.
  • Eisai
  • Eli Lilly And CoMPany
  • Genentech
  • Glaxosmith
  • Merck & Co. Inc.
  • Novartis International
  • Pfizer
  • Qiagen N.V. CoMPany
  • Pharmacyclics
  • Roche
  • Sanofi
  • Teva Pharmaceuticals
  • Ventana
  • Valeant Pharmaceutical
  • Varian Medical Systems
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll